NitaLSeibelMD

Pediatric Hematology & Oncology • Rockville, MD

Head, Pediatric Solid Tumor Therapeutics

Join to view full profile

Dr. Seibel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Seibel's full profile

Already have an account?

Office
9850 Key West Ave
Rockville, MD 20850
Phone+1 301-765-5400

Fax+1 301-294-0897

Education & Training

National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1984 - 1987
National Capital ConsortiumResidency, Pediatrics, 1984 - 1986
Nationwide Children's Hospital/Ohio State UniversityResidency, Pediatrics, 1981 - 1983
Ohio State University College of MedicineClass of 1981

Certifications & Licensure

OH State Medical License 1987 - 2026
MD State Medical License 1988 - 2025
VA State Medical License 1988 - 2018
DC State Medical License 1988 - 2014
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia Start of enrollment: 1996 Sep 01
Completed
Phase 3

Publications & Presentations

PubMed

Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric...
Theodore W Laetsch, Kathleen Ludwig, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton
JCO Precision Oncology. 2024-09-01
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group P...
Margaret E Macy, Rajen Mody, Joel M Reid, Jin Piao, Lauren Saguilig
JCO Precision Oncology. 2024-09-01
1 citations
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G.
Marie V Nelson, AeRang Kim, P Mickey Williams, Sinchita Roy-Chowdhuri, David R Patton
The Oncologist. 2024-08-05

Press Mentions

Dexrazoxane Protects the Heart Long Term for Kids Being Treated for CancerMarch 16th, 2023
FDA Committee Unanimously Rejects 131-I-Omburtamab for NeuroblastomaOctober 28th, 2022
$NCI-COG Pediatric MATCH Study Shows Benefit of Genetic Screening in Refractory Tumors$
NCI-COG Pediatric MATCH Study Shows Benefit of Genetic Screening in Refractory TumorsApril 4th, 2022
Join now to see all